Trial Outcomes & Findings for Cytokine Removal in Cardiopulmonary Bypass Patients (NCT NCT01879176)

NCT ID: NCT01879176

Last Updated: 2017-02-23

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

46 participants

Primary outcome timeframe

1. Preoperative 2. Before CBP 3. After CPB 4. 2 hours after CPB 5. 24 hours 6. 48 hours 7. 120 hours

Results posted on

2017-02-23

Participant Flow

Participant milestones

Participant milestones
Measure
CytoSorb
For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 . CytoSorb
Control
No filter will be installed on the CPB machine.
Overall Study
STARTED
24
22
Overall Study
COMPLETED
16
16
Overall Study
NOT COMPLETED
8
6

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Cytokine Removal in Cardiopulmonary Bypass Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
CytoSorb
n=19 Participants
For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1.
Control
n=18 Participants
No filter will be installed on the CPB machine.
Total
n=37 Participants
Total of all reporting groups
Age, Continuous
64 years
n=5 Participants
69 years
n=7 Participants
67 years
n=5 Participants
Gender
Female
7 Participants
n=5 Participants
4 Participants
n=7 Participants
11 Participants
n=5 Participants
Gender
Male
12 Participants
n=5 Participants
14 Participants
n=7 Participants
26 Participants
n=5 Participants
Region of Enrollment
Austria
19 participants
n=5 Participants
18 participants
n=7 Participants
37 participants
n=5 Participants

PRIMARY outcome

Timeframe: 1. Preoperative 2. Before CBP 3. After CPB 4. 2 hours after CPB 5. 24 hours 6. 48 hours 7. 120 hours

Outcome measures

Outcome measures
Measure
CytoSorb
n=16 Participants
For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
Control
n=16 Participants
No filter will be installed on the CPB machine.
IL-6
Preoperative
0 pg/ml
Interval 0.0 to 0.0
0 pg/ml
Interval 0.0 to 0.0
IL-6
Before CPB
0 pg/ml
Interval 0.0 to 0.0
0 pg/ml
Interval 0.0 to 0.0
IL-6
After CPB
62.9 pg/ml
Interval 10.8 to 98.7
63.6 pg/ml
Interval 41.2 to 154.9
IL-6
2 hours after CPB
120.8 pg/ml
Interval 49.0 to 160.8
118.7 pg/ml
Interval 68.4 to 255.9
IL-6
24 hours after CPB
111.6 pg/ml
Interval 53.7 to 253.5
120.9 pg/ml
Interval 68.0 to 198.5
IL-6
48 hours after CPB
89.0 pg/ml
Interval 61.4 to 160.5
67.7 pg/ml
Interval 43.7 to 134.5
IL-6
120 hours after CPB
0.4 pg/ml
Interval 0.0 to 8.3
8.2 pg/ml
Interval 0.8 to 19.4

Adverse Events

CytoSorb

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Martin H. Bernardi

Medical University of Vienna

Phone: 004314040041090

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place